Suppr超能文献

B细胞淋巴瘤-2(Bcl-2)小分子功能转化剂抑制乳腺癌肺转移。

Small Molecule Functional Converter of B-Cell Lymphoma-2 (Bcl-2) Suppresses Breast Cancer Lung Metastasis.

作者信息

Kopparapu Prasad R, Löhr Christiane V, Pearce Martin C, Tyavanagimatt Shanthakumar, Nakshatri Harikrishna, Kolluri Siva K

机构信息

Cancer Research Laboratory, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon 97331-8580, United States.

Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon 97331-4801, United States.

出版信息

ACS Pharmacol Transl Sci. 2024 May 1;7(5):1302-1309. doi: 10.1021/acsptsci.3c00360. eCollection 2024 May 10.

Abstract

The B-cell lymphoma-2 (Bcl-2) family of proteins plays a vital role in tumorigenesis. Cancer cells utilize the expression of Bcl-2 to evade therapy and develop resistance. Bcl-2 overexpression also causes cancer cells to be more invasive and metastatic. About 80% of cancer deaths are due to metastases, and yet targeted therapies for metastatic cancers are scarce. We discovered a small molecule, BFC1103, which changes the conformation of Bcl-2 to convert the antiapoptotic protein to a proapoptotic protein. BFC1103-induced apoptosis is dependent on the expression levels of Bcl-2, with higher levels causing more apoptosis. BFC1103 suppressed the growth of breast cancer lung metastasis. BFC1103 has the potential for further optimization and development for clinical testing in metastatic cancers that express Bcl-2. This study demonstrates a new approach to target Bcl-2 using a small molecule, BFC1103, to suppress metastatic disease.

摘要

B细胞淋巴瘤-2(Bcl-2)蛋白家族在肿瘤发生过程中起着至关重要的作用。癌细胞利用Bcl-2的表达来逃避治疗并产生耐药性。Bcl-2的过度表达还会使癌细胞更具侵袭性和转移性。约80%的癌症死亡是由转移所致,然而针对转移性癌症的靶向治疗却很匮乏。我们发现了一种小分子BFC1103,它能改变Bcl-2的构象,将抗凋亡蛋白转变为促凋亡蛋白。BFC1103诱导的细胞凋亡依赖于Bcl-2的表达水平,表达水平越高,凋亡越多。BFC1103抑制了乳腺癌肺转移的生长。BFC1103有进一步优化和开发的潜力,可用于对表达Bcl-2的转移性癌症进行临床试验。本研究展示了一种利用小分子BFC1103靶向Bcl-2以抑制转移性疾病的新方法。

相似文献

本文引用的文献

4
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials.Bcl-2 通路抑制在实体瘤中的临床研究进展。
Clin Transl Oncol. 2023 Jun;25(6):1554-1578. doi: 10.1007/s12094-022-03070-9. Epub 2023 Jan 13.
6
BCL-2 protein family: attractive targets for cancer therapy.BCL-2 蛋白家族:癌症治疗的诱人靶点。
Apoptosis. 2023 Feb;28(1-2):20-38. doi: 10.1007/s10495-022-01780-7. Epub 2022 Nov 7.
8
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics.适应生存:用 BH3 模拟物靶向癌细胞。
Cancer Discov. 2022 May 2;12(5):1217-1232. doi: 10.1158/2159-8290.CD-21-1334.
10
It's time to die: BH3 mimetics in solid tumors.是时候死亡了:BH3 模拟物在实体肿瘤中的应用。
Biochim Biophys Acta Mol Cell Res. 2021 Apr;1868(5):118987. doi: 10.1016/j.bbamcr.2021.118987. Epub 2021 Feb 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验